相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Voriconazole metabolism is influenced by severe inflammation: a prospective study
Anette Veringa et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
CYP2C19 Genotype-Dependent Pharmacokinetic Drug Interaction Between Voriconazole and Ritonavir-Boosted Atazanavir in Healthy Subjects
Li Zhu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Therapeutic drug monitoring for invasive mould infections and disease: pharmacokinetic and pharmacodynamic considerations
Katharine E. Stott et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2017)
Pharmacokinetic Evaluation of CYP3A4-Mediated Drug-Drug Interactions of Isavuconazole With Rifampin, Ketoconazole, Midazolam, and Ethinyl Estradiol/Norethindrone in Healthy Adults
Robert Townsend et al.
CLINICAL PHARMACOLOGY IN DRUG DEVELOPMENT (2017)
Worldwide Distribution of Cytochrome P450 Alleles: A Meta-analysis of Population-scale Sequencing Projects
Y. Zhou et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Autoinhibitory properties of the parent but not of the N-oxide metabolite contribute to infusion rate-dependent voriconazole pharmacokinetics
Nicolas Hohmann et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2017)
Clinical Pharmacogenetics Implementation Consortium (CPIC) Guidelines for CYP2C19 and Voriconazole Therapy
B. Moriyama et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2017)
Isavuconazonium sulfate: a triazole prodrug for invasive fungal infections
Derek Murrell et al.
INTERNATIONAL JOURNAL OF PHARMACY PRACTICE (2017)
What Can Be Learned from Recent New Drug Applications? A Systematic Review of Drug Interaction Data for Drugs Approved by the US FDA in 2015
Jingjing Yu et al.
DRUG METABOLISM AND DISPOSITION (2017)
Pharmacogenomics of the cytochrome P450 2C family: impacts of amino acid variations on drug metabolism
Adriana Isvoran et al.
DRUG DISCOVERY TODAY (2017)
Inhibitory Potential of Antifungal Drugs on ATP-Binding Cassette Transporters P-Glycoprotein, MRP1 to MRP5, BCRP, and BSEP
Vincent J. C. Lempers et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2016)
Genotype-Directed Dosing Leads to Optimized Voriconazole Levels in Pediatric Patients Receiving Hematopoietic Stem Cell Transplantation
Ashley Teusink et al.
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION (2016)
Dose-Dependent Bioavailability and CYP3A Inhibition Contribute to Non-Linear Pharmacokinetics of Voriconazole
Nicolas Hohmann et al.
CLINICAL PHARMACOKINETICS (2016)
Effect of cytochrome P450 2C19 polymorphisms on the clinical outcomes of voriconazole: a systematic review and meta-analysis
Xiaofei Li et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2016)
Antifungal Agents Spectrum of Activity, Pharmacology, and Clinical Indications
Jeniel E. Nett et al.
INFECTIOUS DISEASE CLINICS OF NORTH AMERICA (2016)
Impact of CYP2C19 genetic polymorphisms on voriconazole dosing and exposure in adult patients with invasive fungal infections
Fabien Lamoureux et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2016)
Trough concentration of voriconazole and its relationship with efficacy and safety: a systematic review and meta-analysis
Haiying Jin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2016)
The Effect of Genetic Polymorphism on the Inhibition of Azole Antifungal Agents Against CYP2C9-Mediated Metabolism
Toshiro Niwa et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2016)
CYP2C9 polymorphisms and phenytoin metabolism: implications for adverse effects
Valentina Franco et al.
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2015)
Effects of CYP3A4 polymorphisms on the plasma concentration of voriconazole
H. -R. He et al.
EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES (2015)
Therapeutic Drug Monitoring and Genotypic Screening in the Clinical Use of Voriconazole
Brad Moriyama et al.
CURRENT FUNGAL INFECTION REPORTS (2015)
Fungal Biomarkers, Antifungal Susceptibility Testing, and Therapeutic Drug Monitoring-Practical Applications for the Clinician in a Tertiary Care Center
Jarrett R. Amsden
CURRENT FUNGAL INFECTION REPORTS (2015)
Plasma Fluoride Level as a Predictor of Voriconazole-Induced Periostitis in Patients With Skeletal Pain
Woo J. Moon et al.
CLINICAL INFECTIOUS DISEASES (2014)
The Role of Pharmacogenetics in the Disposition of and Response to Tacrolimus in Solid Organ Transplantation
Dennis A. Hesselink et al.
CLINICAL PHARMACOKINETICS (2014)
Functional Gene Variants of CYP3A4
A. N. Werk et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2014)
Consensus guidelines for optimising antifungal drug delivery and monitoring to avoid toxicity and improve outcomes in patients with haematological malignancy, 2014
M. M. Chau et al.
INTERNAL MEDICINE JOURNAL (2014)
Efficacy and safety of voriconazole and CYP2C19 polymorphism for optimised dosage regimens in patients with invasive fungal infections
Taotao Wang et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2014)
Understanding variability with voriconazole using a population pharmacokinetic approach: implications for optimal dosing
Michael J. Dolton et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2014)
Voriconazole Metabolism, Toxicity, and the Effect of Cytochrome P450 2C19 Genotype
Dimitrios Zonios et al.
JOURNAL OF INFECTIOUS DISEASES (2014)
CYP2C19 Polymorphisms and Therapeutic Drug Monitoring of Voriconazole: Are We Ready for Clinical Implementation of Pharmacogenomics?
Aniwaa Owusu Obeng et al.
PHARMACOTHERAPY (2014)
Relative Contributions of Cytochrome CYP3A4 Versus CYP3A5 for CYP3A-Cleared Drugs Assessed In Vitro Using a CYP3A4-Selective Inactivator (CYP3cide)
Elaine Tseng et al.
DRUG METABOLISM AND DISPOSITION (2014)
Impact of Genetic Polymorphisms in CYP2C9 and CYP2C19 on the Pharmacokinetics of Clinically Used Drugs
Takeshi Hirota et al.
DRUG METABOLISM AND PHARMACOKINETICS (2013)
Effect of itraconazole on the concentrations of tacrolimus and cyclosporine in the blood of patients receiving allogeneic hematopoietic stem cell transplants
Miho Nara et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2013)
Correlation of CYP2C19 Phenotype With Voriconazole Plasma Concentration in Children
Atsushi Narita et al.
JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY (2013)
Clinical Impact of Cytochrome P450 2C19 Genotype on the Treatment of Invasive Aspergillosis under Routine Therapeutic Drug Monitoring of Voriconazole in a Korean Population
Si-Hyun Kim et al.
INFECTION AND CHEMOTHERAPY (2013)
Multicenter Study of Posaconazole Therapeutic Drug Monitoring: Exposure-Response Relationship and Factors Affecting Concentration
Michael J. Dolton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Prospective, Observational Study of Voriconazole Therapeutic Drug Monitoring among Lung Transplant Recipients Receiving Prophylaxis: Factors Impacting Levels of and Associations between Serum Troughs, Efficacy, and Toxicity
Dimitra Mitsani et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
Multicenter Study of Voriconazole Pharmacokinetics and Therapeutic Drug Monitoring
Michael J. Dolton et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2012)
The Effect of Therapeutic Drug Monitoring on Safety and Efficacy of Voriconazole in Invasive Fungal Infections: A Randomized Controlled Trial
Wan Beom Park et al.
CLINICAL INFECTIOUS DISEASES (2012)
Challenging Recommended Oral and Intravenous Voriconazole Doses for Improved Efficacy and Safety: Population Pharmacokinetics-Based Analysis of Adult Patients With Invasive Fungal Infections
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2012)
Evidence of CYP3A Allosterism In Vivo: Analysis of Interaction Between Fluconazole and Midazolam
J. Yang et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2012)
Effect of CYP2C19 Polymorphism on the Pharmacokinetics of Voriconazole After Single and Multiple Doses in Healthy Volunteers
SeungHwan Lee et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Investigation and threshold of optimum blood concentration of voriconazole: a descriptive statistical meta-analysis
Yukihiro Hamada et al.
JOURNAL OF INFECTION AND CHEMOTHERAPY (2012)
Effect of cytochrome P450 2C19 genotype on voriconazole exposure in cystic fibrosis lung transplant patients
Maud Berge et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2011)
Triazole antifungal agents drug-drug interactions involving hepatic cytochrome P450
Paul O. Gubbins
EXPERT OPINION ON DRUG METABOLISM & TOXICOLOGY (2011)
Current Concepts in Antifungal Pharmacology
Russell E. Lewis
MAYO CLINIC PROCEEDINGS (2011)
Pharmacogenomics of the triazole antifungal agent voriconazole
Gerd Mikus et al.
PHARMACOGENOMICS (2011)
Increasing the dose of voriconazole compensates for enzyme induction by phenytoin
Isabel Spriet et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Pharmacogenetics of CYP2C19: functional and clinical implications of a new variant CYP2C19*17
Alain Li-Wan-Po et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Potential impact of cytochrome P450 3A5 in human liver on drug interactions with triazoles
Hiroshi Yamazaki et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Update Information on Drug Metabolism Systems— 2009, Part I
F. Peter Guengerich et al.
CURRENT DRUG METABOLISM (2010)
Update Information on Drug Metabolism Systems-2009, Part II. Summary of Information on the Effects of Diseases and Environmental Factors on Human Cytochrome P450 (CYP) Enzymes and Transporters
Slobodan Rendic et al.
CURRENT DRUG METABOLISM (2010)
In Vitro Hepatic Metabolism Explains Higher Clearance of Voriconazole in Children versus Adults: Role of CYP2C19 and Flavin-Containing Monooxygenase 3
Souzan B. Yanni et al.
DRUG METABOLISM AND DISPOSITION (2010)
Investigation into UDP-Glucuronosyltransferase (UGT) Enzyme Kinetics of Imidazole- and Triazole-Containing Antifungal Drugs in Human Liver Microsomes and Recombinant UGT Enzymes
Karine Bourcier et al.
DRUG METABOLISM AND DISPOSITION (2010)
Fluconazole-induced intoxication with phenytoin in a patient with ultra-high activity of CYP2C9
Anders Hellden et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
Effects of erythromycin on voriconazole pharmacokinetics and association with CYP2C19 polymorphism
Hui-Yan Shi et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2010)
The pharmacokinetics of fluconazole in healthy Chinese adult volunteers: influence of ethnicity and gender
T. Guo et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2010)
Comprehensive In Vitro Analysis of Voriconazole Inhibition of Eight Cytochrome P450 (CYP) Enzymes: Major Effect on CYPs 2B6, 2C9, 2C19, and 3A
Seongwook Jeong et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2009)
Pharmacokinetics, metabolism and bioavailability of the triazole antifungal agent voriconazole in relation to CYP2C19 genotype
Ina Scholz et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Effects of Oral Posaconazole on the Pharmacokinetic Properties of Oral and Intravenous Midazolam: A Phase I, Randomized, Open-Label, Crossover Study in Healthy Volunteers
Gopal Krishna et al.
CLINICAL THERAPEUTICS (2009)
Genetic Polymorphism of the Human Cytochrome P450 2C9 Gene and Its Clinical Significance
Bo Wang et al.
CURRENT DRUG METABOLISM (2009)
Polymorphism of human cytochrome P450 enzymes and its clinical impact
Shu-Feng Zhou et al.
DRUG METABOLISM REVIEWS (2009)
The CYP2C19 ultra-rapid metabolizer genotype influences the pharmacokinetics of voriconazole in healthy male volunteers
Guo Wang et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Correlation between voriconazole trough plasma concentration and hepatotoxicity in patients with different CYP2C19 genotypes
Kazuaki Matsumoto et al.
INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS (2009)
Monitoring trough concentration of voriconazole is important to ensure successful antifungal therapy and to avoid hepatic damage in patients with hematological disorders
Koki Ueda et al.
INTERNATIONAL JOURNAL OF HEMATOLOGY (2009)
CYP2C19 Genotype Is a Major Factor Contributing to the Highly Variable Pharmacokinetics of Voriconazole
Johanna Weiss et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2009)
Therapeutic Drug Monitoring of Antifungals: Pharmacokinetic and Pharmacodynamic Considerations
Jeannina Smith et al.
THERAPEUTIC DRUG MONITORING (2009)
Cytochrome P450 and chemical toxicology
F. Peter Guengerich
CHEMICAL RESEARCH IN TOXICOLOGY (2008)
Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes
Andres Pascual et al.
CLINICAL INFECTIOUS DISEASES (2008)
Role of flavin-containing monooxygenase in oxidative metabolism of voriconazole by human liver microsomes
Souzan B. Yanni et al.
DRUG METABOLISM AND DISPOSITION (2008)
Differential genotype dependent inhibition of CYP2C9 in humans
Vikas Kumar et al.
DRUG METABOLISM AND DISPOSITION (2008)
Life-threatening serotonin toxicity due to a citalopram-fluconazole drug interaction: case reports and discussion
Tomer T. Levin et al.
GENERAL HOSPITAL PSYCHIATRY (2008)
Pharmacokinetic interaction between voriconazole and efavirenz at steady state in healthy male subjects
Ping Liu et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2008)
Effects of CYP3A5 and MDR1 single nucleotide polymorphisms on drug interactions between tacrolimus and fluconazole in renal allograft recipients
Dirk R. Kuypers et al.
PHARMACOGENETICS AND GENOMICS (2008)
Contribution of itraconazole metabolites to inhibition of CYP3A4 in vivo
I. E. Templeton et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2008)
The influence of CYP3A5 expression on the extent of hepatic CYP3A inhibition is substrate-dependent: An in vitro-in vivo evaluation
Nina Isoherranen et al.
DRUG METABOLISM AND DISPOSITION (2008)
Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP)
Anshul Gupta et al.
JOURNAL OF PHARMACEUTICAL SCIENCES (2007)
Hepatotoxicity of oral and intravenous voriconazole in relation to cytochrome P450 polymorphisms
Mark-David Levin et al.
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY (2007)
Steady-state pharmacokinetic and safety profiles of voriconazole and ritonavir in healthy male subjects
Ping Liu et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2007)
Roles of CYP3A4 and CYP2C19 in methyl hydroxylated and N-oxidized metabolite formation from voriconazole, a new anti-fungal agent, in human liver microsomes
Norie Murayama et al.
BIOCHEMICAL PHARMACOLOGY (2007)
Visible spectra of type II cytochrome P450-drug complexes: Evidence that incomplete heme coordination is common
Charles W. Locuson et al.
DRUG METABOLISM AND DISPOSITION (2007)
Potent cytochrome P4502C19 genotype-related interaction between voriconazole and the cytochrome P450 3A4 inhibitor ritonavir
Gerd Mikus et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Effect of CYP3A5 polymorphism on tacrolimus metabolic clearance in vitro
Y Dai et al.
DRUG METABOLISM AND DISPOSITION (2006)
Voriconazole therapeutic drug monitoring
J Smith et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Effect of voriconazole on the pharmacokinetics and pharmacodynamics of intravenous and oral midazolam
TI Saari et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2006)
Stereochemical aspects of itraconazole metabolism in vitro and in vivo
KL Kunze et al.
DRUG METABOLISM AND DISPOSITION (2006)
Investigation of the potential relationships between plasma voriconazole concentrations and visual adverse events or liver function test abnormalities
K Tan et al.
JOURNAL OF CLINICAL PHARMACOLOGY (2006)
Safety of voriconazole in a patient with CYP2C9*2/CYP2C9*2 genotype
Marcus J. P. Geist et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2006)
Effect of antifungal drugs on cytochrome P450 (CYP) 2C9, CYP2C19, and CYP3A4 activities in human liver microsomes
T Niwa et al.
BIOLOGICAL & PHARMACEUTICAL BULLETIN (2005)
Effect of itraconazole on the pharmacokinetics and pharmacodynamics of fexofenadine in relation to the MDR1 genetic polymorphism
JH Shon et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2005)
Bioequivalence evaluation of two formulations of fluconazole 150 mg capsule in healthy Arab men
E Al-Gaai et al.
BIOPHARMACEUTICS & DRUG DISPOSITION (2005)
Influence of CYP2C9 polymorphisms, demographic factors and concomitant drug therapy on warfarin metabolism and maintenance dose
D Herman et al.
PHARMACOGENOMICS JOURNAL (2005)
Identification of human UDP-glucuronosyltransferase enzyme(s) responsible for the glucuronidation of posaconazole (Noxafil)
A Ghosal et al.
DRUG METABOLISM AND DISPOSITION (2004)
Role of itraconazole metabolites in CYP3A4 inhibition
N Isoherranen et al.
DRUG METABOLISM AND DISPOSITION (2004)
Disposition of posaconazole following single-dose oral administration in healthy subjects
P Krieter et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2004)
Effect of the CYP3A5 genotype on the pharmacokinetics of intravenous midazolam during inhibited and induced metabolic states
KS Yu et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
Evidence of significant contribution from CYP3A5 to hepatic drug metabolism
WL Huang et al.
DRUG METABOLISM AND DISPOSITION (2004)
Comparison of the pharmacokinetics of fosfluconazole and fluconazole after single intravenous administration of fosfluconazole in healthy Japanese and Caucasian volunteers
S Sobue et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2004)
Pharmacokinetics of voriconazole and cytochrome P450 2C19 genetic status
Y Ikeda et al.
CLINICAL PHARMACOLOGY & THERAPEUTICS (2004)
The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human
SJ Roffey et al.
DRUG METABOLISM AND DISPOSITION (2003)
Identification of the cytochrome P450 enzymes involved in the N-oxidation of voriconazole
R Hyland et al.
DRUG METABOLISM AND DISPOSITION (2003)
Effect of omeprazole on the steady-state pharmacokinetics of voriconazole
N Wood et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
No clinically significant effect of erythromycin or azithromycin on the pharmacokinetics of voriconazole in healthy male volunteers
L Purkins et al.
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (2003)
Pharmacogenetics of CYP2C9 and interindividual variability in anticoagulant response to warfarin
H Takahashi et al.
PHARMACOGENOMICS JOURNAL (2003)
Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens
L Purkins et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Interaction of common azole antifungals with P glycoprotein
EJ Wang et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY (2002)
Efficacy and safety of voriconazole in the treatment of acute invasive aspergillosis
DW Denning et al.
CLINICAL INFECTIOUS DISEASES (2002)
Sequence diversity in CYP3A promoters and characterization of the genetic basis of polymorphic CYP3A5 expression
P Kuehl et al.
NATURE GENETICS (2001)
Risk assessment for antimicrobial agent-induced QTc interval prolongation and torsades de pointes
RC Owens
PHARMACOTHERAPY (2001)
分享论文
